Tesamorelin plus ipamorelin: a blend that no study has tested, and the class-level synergy its rationale is borrowed from

No study has tested it. Not one indexed paper gives tesamorelin and ipamorelin to the same person, or the same animal. The combination section below is empty and stays empty.

The reasoning behind it is real. The two raise growth hormone through different doors: tesamorelin copies the releasing hormone the hypothalamus sends to the pituitary, and ipamorelin acts on the ghrelin receptor, a separate system. Giving one of each releases more growth hormone than either alone, which was shown in people in the 1990s using a different releasing peptide.

What that supports is a bigger pulse, not a result. No trial has followed a combination to any outcome a person would notice.

The blend adds its own problem. A pre-mixed vial fixes a ratio that nobody chose on evidence, and forces one schedule onto two compounds studied on different ones.

Each component is well documented on its own. Tesamorelin has an approval and phase 3 trials, in one population. Ipamorelin's one large randomised trial missed its endpoint.

A search of the indexed literature for papers naming both compounds returns none. There is no randomised trial, no observational study, no case series and no animal study of tesamorelin with ipamorelin.

That is not a limitation of this page's ledger. It is what the combination's evidence base consists of, and it should be read against the fact that the blend is sold by at least two vendors ranking on the first page of results for its own name.

Everything below is therefore one of two things: evidence about a class of combination, which exists and is decades old, or evidence about each component separately, which is substantial for one of them and thin for the other. Neither becomes evidence for this pair by being placed next to it.

The pituitary releases growth hormone under two controls: growth hormone-releasing hormone, which tells it to, and somatostatin, which tells it not to. A third system, the ghrelin receptor, acts on both the pituitary and the hypothalamus.

Tesamorelin is an analogue of the releasing hormone. Ipamorelin is a growth hormone secretagogue acting at the ghrelin receptor. Combining a releasing hormone with a secretagogue is a standard pharmacological idea, and the human evidence for it is specific: a 1995 study described a striking synergistic action on GH release when a releasing peptide and the releasing hormone were given together, and used patients whose hypothalamus was disconnected from the pituitary to show that the peptide's main action is exerted at the hypothalamic level. A 1991 paper had already described the releasing peptide's dual site of action on hypothalamus and pituitary.

The 1995 study put it in one sentence: In man, GHRP-6 is more efficacious than GHRH, and a striking synergistic action on GH release is observed when GHRP-6 and GHRH are administered simultaneously. A companion study in children whose pituitary stalk had been severed found no growth hormone response to either compound or to both together, which is how the hypothalamic component of the effect was established.

Two things weaken the transfer of that finding to this blend. The synergy studies used GHRP-6, not ipamorelin; ipamorelin is a later, more selective compound from the same family, chosen for not raising cortisol and prolactin, and its selectivity is the reason to expect its behaviour in combination to differ. And the studies measured growth hormone in the blood over hours, as endocrine tests, not body composition, strength or anything else over months.

The dual-site idea is older still. A 1991 paper described the releasing hexapeptide as acting by a unique and complementary dual site of action on the hypothalamus and pituitary, which is the mechanism the whole class of combinations is built on, and a 1997 review noted that releasing peptides have no structural homology with GHRH and act via specific receptors present either at the pituitary or the hypothalamic level.

A 2008 review put the general question well in its title, asking whether releasing hormone and secretagogues in normal ageing are a fountain of youth or a pool of Tantalus. Its answer, for the class, was that adult growth hormone deficiency is a real entity where replacement helps, and that normal ageing resembles it without being it.

The two results in full. Tesamorelin's pivotal trial reported that the measure of visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group, and its pooled phase 3 analysis concluded that treatment reduces VAT and maintains the reduction for up to 52 wk, preserves abdominal sc adipose tissue, improves body image and lipids, and is overall well tolerated without clinically meaningful changes in glucose parameters. Ipamorelin's trial in postoperative ileus reported that there were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses, while its earlier pharmacology showed it induces the release of GH at all dose levels.

The asymmetry matters more than any synergy argument. Tesamorelin's evidence is real but narrow: it was tested in people with HIV-associated visceral fat accumulation and approved for them. Ipamorelin's largest human trial, in recovery of bowel function after surgery, did not beat placebo, which is a fact almost no page selling the blend mentions.

Full records: ipamorelin, and tesamorelin's trial detail sits in the sermorelin versus tesamorelin comparison while its own record is unwritten.

Most of the search volume for this pair is for the word blend, which is a product rather than a question. Two vendors selling it rank in the top ten for the combination's own name.

A blend makes three decisions on the buyer's behalf, none of them from evidence:

• The ratio. How much of each, fixed in the vial. No trial chose it, because no trial gave both.
• The schedule. Tesamorelin's trials dosed once daily. A secretagogue's effect is a pulse of growth hormone within minutes of a dose, which is the argument usually made for dosing it more than once a day. One vial can only be injected on one schedule, so combining them means abandoning one of those rhythms.
• The identity of the tesamorelin. The trials quoted for this half of the blend used the approved product. What is in a research blend is not that, and nobody has shown the two are equivalent.

None of this makes a blend useless. It makes the evidence on this page evidence about other things, which is the honest description of every claim made for it.

Tesamorelin was given at 2 mg once daily by subcutaneous injection in the trials behind its approval, for 26 to 52 weeks. Ipamorelin's doses come from early growth hormone-release studies and from its one large trial; its record carries them with their sources.

There is no published dose for the two together, so none appears here. The figures circulating for the blend come from vendors and clinics, and this site's boundary is that a dose appears when a study or a label gave it. Each component's own figures are on its record: ipamorelin doses.

Tesamorelin: injection-site reactions most consistently, with no clinically meaningful change in glucose parameters in the pooled phase 3 analysis. Fluid retention, joint pain and carpal tunnel symptoms are the class effects of raising growth hormone.

Ipamorelin: selected during development for not raising cortisol or prolactin, which distinguishes it from the earlier releasing peptides, and described as well tolerated in its trials, including the one that missed its endpoint.

For the combination there is nothing. Two agents that raise growth hormone through different systems might produce more of the same class effects, or might not; the growth hormone pulse is larger in the class studies, and whether that translates into more fluid retention or more effect on blood sugar has not been measured for any such pair over time.

Studied: tesamorelin in adults with HIV-associated visceral fat; ipamorelin in adults recovering from bowel surgery and in early endocrine studies. Never studied: the combination, in anyone.

Discussed for: body recomposition, visceral fat, sleep and recovery in people with none of the conditions above, which is the gap between the evidence and the market.

The unresolved questions are the ordinary ones for raising growth hormone over time: what it does to blood sugar and insulin sensitivity, whether fluid retention and joint symptoms accumulate, and whether raising growth hormone in someone whose own secretion is normal produces any durable benefit. The 2008 review in this ledger frames that last question for the whole class and does not answer it.

Tesamorelin is an approved medicine for one indication. Ipamorelin has no approval in any country and is sold as a research chemical. A pre-mixed blend of the two is not an approved product anywhere, and the approval attaching to one component does not extend to a compound preparation containing it.

Both are prohibited in sport as growth hormone secretagogues. Neither has been assessed by a regulator in blended form, and no regulator has evaluated what is in a research vial.

1. Citing GHRH-plus-GHRP synergy as evidence for this blend. Those studies used GHRP-6 and measured growth hormone in the blood over hours.
2. Carrying tesamorelin's trial results across. They were in people with HIV-associated visceral fat, using the approved product.
3. Omitting that ipamorelin's largest trial missed its endpoint. It found no significant difference from placebo.
4. Treating a blend's ratio as a protocol. It is a manufacturing decision.
5. Assuming more growth hormone means more benefit. The class studies measured the pulse, not the outcome.
6. Reading the empty combination section as a gap. It is the finding.